# A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

> **NCT00513253** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00513253
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-04
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It was determined not to be needed based on the clinical development plan of Tykerb.
- **Last updated:** 2015-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513253, "A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00513253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*